Neuralstem (CUR) Agrees to a Sponsor Research Agreement with China Medical University in Taiwan
More News related to CUR
- Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
- Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
- /R E P E A T -- DiagnoCure signs distribution agreement in the UK for its colorectal cancer test/
- DiagnoCure signs distribution agreement in the UK for its colorectal cancer test
- Unusual 11 Mid-Day Movers 9/21: CHIP, PER, HNSN, CUR Higher; DPTR, BUSE, IBNK, RPRX Lower
More News related to Corporate News
- Financial Group Moving Higher Amid BofA TARP Repayment News (BAC, C, WFC, XLF, FAS)
- Lexington Realty Trust (LXP) Sells Office Facility in Columbia, SC
- BofA (BAC) Confirms That It Will Repay $45B in TARP Funds
- EQT Corp.'s (EQT) Board Approves Capital Budget for 2010
- Morgan Stanley (MS) may restructure its real estate fund -WSJ
Neuralstem, Inc. (Amex: CUR) announced today that it has entered into a sponsored research agreement with the China Medical University & Hospital of Taiwan, in Taichung, Taiwan, to prepare for a human clinical trial using Neuralstem's human spinal cord neural stem cells to treat stroke patients. The therapy will focus on patients whose post-stroke symptoms, including complete or partial paralysis, have stopped improving more than six months after an ischemic stroke. Ischemic stroke, caused by a blockage in a vessel supplying blood to the brain, is the most common type of stroke and affects more than 400,000 people in the United States yearly. There are about 6.5 million stroke survivors in the U.S. alone.
Related Categories
Corporate NewsStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
